Aucta Pharmaceuticals signs commercial manufacturing agreement with Catalent

By ROI-NJ Staff
Somerset | Sep 5, 2018 at 7:10 am

Somerset-based Catalent Pharma Solutions, a provider of delivery technologies and development solutions for consumer health products, announced a commercial supply agreement with Aucta Pharmaceuticals Inc.‘s vigabatrin.

The agreement follows a development program to formulate vigabatrin into a novel dosage that employs Catalent’s FlexDose services. Aucta’s commercial partner, Upsher-Smith Laboraties LLC, will launch vigabatrin under the brand name Vigadrone.

“Catalent has over a decade of experience in developing, manufacturing and packaging stick pack products, which offer a number of advantages to improve the convenience of dosing and patient adherence of drug products,” Jonathan Arnold, Catalent’s president, oral drug delivery, said.

ROI-NJ Staff | | @roinjnews